Attempts to obtain mice reconstituted with a human immune system (HIS) mice, also referred to as HIS mice, date back to the end of 1980s, when mice carrying the Prkdc^scid^ mutation were first used as recipients of human progenitors, with limited success ([@bib28]). In the last decade, mice with engineered combined immunodeficiencies were obtained and a more efficient engraftment of human hematopoietic stem cells (HSC) was described ([@bib28]; [@bib19]; [@bib3]). Even though the full human reconstitution is generally not achieved, HIS mice have already given valuable results for a better understanding of the differentiation potential of human immune populations ([@bib9]; [@bib20]) and for the study of viral human pathogens ([@bib16]). Moreover, HIS mice are interesting models for human vaccine development ([@bib12]; [@bib1]). Human immune system mice, could provide new experimental models to study the relationships between human tumours and human immune effectors ([@bib3]; [@bib34]).

BALB/c *Rag2*^−/−^;*Il2rg*^−/−^ (hereafter referred to as BRG mice), display a severe combined immunodeficiency, with absence of T, B and NK cells ([@bib25]). These mice can unveal growth and metastatic ability of human xenografts, otherwise not apparent in mice with partial immunodeficiencies ([@bib23]). BALB/c *Rag2*^−/−^;*Il2rg*^−/−^ mice have been effectively used to obtain HIS mice ([@bib32]; [@bib3]) and to test antitumour activity of human immune effectors ([@bib31]). We exploited these features to study the possibility to induce immune responses against human cancer cells by human lymphocytes and their ability to control tumour growth and metastasis.

As the tumoural counterpart, we selected a HER-2-positive human cancer cell line. Therapeutic targeting of HER-2-overexpressing cancers with the humanised monoclonal antibody trastuzumab has already entered the clinical practice, but the search for active immunisation strategies against HER-2 is also pursued ([@bib35]). In transgenic models of HER-2-driven mammary carcinogenesis, immune targeting of HER-2 with both active and passive approaches has shown preventive and therapeutic activity ([@bib17]). Transgenic models are suitable to study, at best, the murine immune response against the transgenic human HER-2 molecule, but cellular or soluble immune effectors elicited in transgenic mice are not of human origin.

In the first part of this study we investigated the reconstituting ability of two types of HSC sorted from human cord blood: CD34^+^ and CD133^+^ cells. CD34^+^ progenitors have been extensively used to obtain HIS mice, see for BRG the pioneering study of [@bib32]. CD133^+^ HSC engraftment was reported after *in vitro* culture in growth factor-supplemented medium ([@bib7]), whereas studies with freshly isolated CD133+ HSC in BRG mice and a direct comparison with CD34+ HSC engraftment ability have not been reported. Subsequently, we investigated the ability to elicit an immune response against HER-2-positive human cancer cells.

Materials and methods
=====================

Generation of HIS mice
----------------------

BALB/c *Rag2*^−/−^;*Il2rg*^−/−^ breeders were kindly given by Drs T Nomura and M Ito of the Central Institute for Experimental Animals (Kawasaki, Japan), then mice were bred in our animal facilities under sterile conditions. Human immune system mice were generated as described ([@bib32]). For details see [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}. Cord blood mononuclear cells were enriched by Ficoll-Hypaque (Amersham Bioscience, Piscataway, NJ, USA) and then processed by MiniMacs high-gradient magnetic separation column (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain highly purified cells (mean purity 93%±6%) as previously described ([@bib27]). For challenge experiments, CD34^+^ or CD133^+^ cells were purchased from AllCells (Emeryville, CA, USA). All the experiments were authorised by the Animal Care and Use Committee of the University of Bologna, and done according to Italian and European guidelines.

Monitoring of HIS mice engraftment
----------------------------------

To assess the level of engraftment and human leukocyte populations, HIS mice were bled every 5 weeks from a tail vein. At the time of killing, the bone marrow (from a femur), spleen, thymus and mesenteric lymph node were collected, spleen cell suspensions were subjected to red blood cell lysis. Cell yield of each organ was determined by staining with Turk\'s solution and counting in a hemocytometer. Human leukocyte populations were analysed by direct immunofluorescence using PE- or FITC-conjugated antibodies purchased from BD Pharmingen, San Diego, CA, USA). PE- and FITC-conjugated mouse IgG1 isotype control antibodies were also used. Fluorescence-activated cell sorting (FACS) analysis was performed with FACScan (Becton Dickinson, St Jose, CA, USA).

Vaccination and tumour challenge
--------------------------------

At 6 weeks HIS mice were distributed into two groups with matched levels of CD45+ human circulating cells. A group was subjected to two cycles of anti-HER-2 cell vaccination according to a schedule previously reported highly effective in HER-2/neu transgenic models ([@bib22]). Cell vaccine consisted of the human HER-2-positive SK-OV-3 cancer cells, with a high membrane expression of human HER-2. SK-OV-3 cell line was authenticated by DNA fingerprinting on the 11 November 2010 (performed by DSMZ, Braunschweig, Germany). Mice received four i.p. vaccinations distributed in 2 weeks consisting of 2 × 10^6^ mitomycin-treated cells (to block proliferation) in 0.4 ml PBS. In the third week mice received five times daily administration of recombinant human IL-12 (PeproTech, Rocky Hill, NJ, USA) in 0.2 ml PBS supplemented with 0.01% mouse serum albumin (Sigma Aldrich, St Louis, MO, USA). The dose of IL-12 was 50 ng per mouse per day in the first 4-week cycle and 100 ng per mouse per day in all subsequent cycles. The fourth-week mice received no treatment. The 4-week vaccination cycle was repeated twice. Non-vaccinated group received the injection of PBS or PBS supplemented with mouse serum albumin.

Vaccinated and non-vaccinated HIS mice, at the age of 17 weeks, received the s.c. injection of 10^5^ live SK-OV-3 cells in 0.2 ml PBS in a flank. Mice were monitored twice weekly for tumour growth by measuring tumour volume, calculated as *π*·\[√(*a·b)*\]^3^/6, where *a*=maximal tumour diameter and *b*=tumour diameter perpendicular to *a*. Mice were killed 40 days after tumour challenge, subjected to an accurate necropsy, tumours and lymphoid organs were collected and processed as reported in other sections. Lungs were fixed in Fekete\'s solution and metastases were counted using a dissection microscope.

Tumour-infiltrating populations
-------------------------------

For histological and immunohistochemical analyses tumours were divided in two pieces: half was fixed in buffered formalin and embedded in paraffin, half was fixed in periodate lysine paraformaldehyde, cryoprotected in sucrose and frozen in OCT. For details see [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Human cytokine production
-------------------------

Cells harvested from lymphoid organs were cultured *in vitro* for 6 days in RPMI 1640 supplemented with 10% fetal bovine serum and with recombinant human IL-2 (50 units ml^−1^, PeproTech). Concentration of human cytokines in culture supernatants as well as in plasma samples was determined with the Bio-Plex 200 suspension array system (Bio-Rad, Milan, Italy) ([@bib5]). Production of human interferon (IFN)-*γ* was also determined by ELISA (Quantikine Human IFN-*γ*, R&D Systems, Minneapolis, MN, USA).

Human antibodies
----------------

Concentration of total human IgM and IgG in plasma from HIS mice was determined by ELISA (Human IgM and Human IgG ELISA quantitation kits, Bethyl Laboratories, Montgomery, TX, USA). Human reference serum (0.38 mg ml^−1^ IgM and 4 mg ml^−1^ IgG, Bethyl Laboratories) was used as a standard. Induction of human antibodies recognising human HER-2/neu was investigated by immunoprecipitation of HER-2-positive cell lysates with plasma samples followed by western blot analysis. For details on detection and *in vitro* activities see [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Engraftment data, antibody levels, cytokine production, tumour volumes and metastases were compared by the Student\'s *t*-test and by the non-parametric Wilcoxon rank sum test. Frequencies were compared by the *χ*^2^ Fisher\'s exact test.

Results
=======

Engraftment of human CD34^+^ and CD133^+^ HSC
---------------------------------------------

Within 24--48 h after birth, BRG mice were subjected to sublethal irradiation and to the intrahepatic injection of 1--2 × 10^5^ CD34^+^ or CD133^+^ human cord blood progenitors. At 5 weeks of age most mice (about 90%) showed at least 10% of circulating human CD45^+^ cells ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). The level of engraftment did not correlate with the number of HSC injected ([Supplementary Figure 1B](#sup1){ref-type="supplementary-material"}). These mice will be hereafter referred to as rCD34 or rCD133, according to the HSC population used for reconstitution, or HIS mice as a whole. The two groups of HIS mice showed similar mean values of circulating human CD45+ and ranges, reaching maximal values of 78% for rCD34 and 71% for rCD133 ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). A long-term persistence of engraftment was obtained, with total circulating human CD45+ over 20--25% up to 20 weeks of age ([Figure 1](#fig1){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}), and a slightly higher persistence for rCD133. Along time, the rise of circulating human CD3+ cells (up to about 30--40% of human CD45+ cells at 20 week) and a parallel decrease of human CD19+ cells were found ([Figure 1](#fig1){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). A significantly higher level of CD19+ cells was observed in rCD133 mice at 10 week.

Human IgM and IgG immunoglobulins became detectable in mice serum 10 weeks after transplantation ([Figure 1](#fig1){ref-type="fig"}); rCD133 mice showed significantly higher serum IgM levels at some time points, but lower IgG levels. The level of early engraftment (at 5--10 week) in rCD34 mice strongly correlated with the rise of human IgM levels, whereas less significant correlations were observed in rCD133 mice and in both HIS mice for IgG levels (data not shown).

Lymphoid organs of rCD34 and rCD133 mice showed similar levels of engrafted human CD45+ cells, up to 50% for the spleen and bone marrow and about 85--95% for thymus and mesentheric lymph node ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Engrafting of human cells also caused an increase in the total number of cells recovered from the thymus, mesentheric lymph node and spleen of HIS mice, whereas non-HIS BRG mice have atrophic or even undetectable thymus and mesentheric lymph node and a low spleen cellularity ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

In conclusion, our data demonstrate, for the first time, the long-term engraftment capacity of CD133^+^ HSC in BRG mice. When compared with CD34^+^ HSC, CD133^+^ cells demonstrated a slightly higher total and B lymphoid reconstitution.

Induction of a human humoral response against HER-2-positive cancer cells
-------------------------------------------------------------------------

To study whether HIS mice can develop an immune response against human cancer cells, at 6 weeks of age HIS rCD34 or rCD133 mice were distributed into two arms with matched levels of CD45+ human circulating cells ([Figure 2A](#fig2){ref-type="fig"}). A group did not receive any further treatment (non-vaccinated group) whereas the other group was vaccinated with proliferation-blocked human HER-2-positive SK-OV-3 cancer cells combined to recombinant human IL-12.

Throughout the vaccination courses, the levels of circulating human CD45+ cells as well as those of other human immune subpopulations ([Figure 2B](#fig2){ref-type="fig"}) showed kinetics similar to those of non-vaccinated HIS mice. A similar rise in total human IgG and IgM antibodies was found at 15 weeks of age in non-vaccinated and vaccinated rCD34 mice ([Figure 3A](#fig3){ref-type="fig"}). Therefore, vaccination *per se* did not affect persistence of human cell engraftment, differentiative ability and production of total antibodies.

At 15 weeks of age sera from vaccinated rCD34 mice showed specific anti-HER-2 IgG antibodies, based on their ability to immunoprecipitate HER-2 from a SK-OV-3 cell lysate ([Figure 3B](#fig3){ref-type="fig"}, lane 4). Sera from non-vaccinated rCD34 mice before challenge did not show any anti-HER-2 immunoprecipitating activity ([Figure 3B](#fig3){ref-type="fig"}, lane 3). Therefore, vaccination was able to elicit production of specific anti-HER-2 human IgG antibodies.

Growth and metastasis of HER-2-positive human cancer cells in HIS mice
----------------------------------------------------------------------

After completion of two vaccination cycles, HIS mice received the s.c. injection of live SK-OV-3 cancer cells. Tumour growth in HIS mice was compared with that of the two groups of non-reconstituted age-matched control mice, run in parallel: untreated BRG mice and mice who only received the same sublethal neonatal irradiation used before reconstitution. A significant inhibition of tumour growth was observed in vaccinated as well as in non-vaccinated rCD34 mice ([Figure 4](#fig4){ref-type="fig"}). A similar behaviour was found in rCD133 mice (data not shown). As SK-OV-3 cells release cytokines and growth factors, such as IL-6, IL- 8 and VEGF (our unpublished results and literature data) ([@bib21]; [@bib11]; [@bib33]), we studied their serum levels in tumour-bearing mice. Human VEGF sera levels in HIS mice were significantly lower than that in non-reconstituted mice ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}), in agreement with the decreased tumour volume. On the contrary, human IL-6 and IL-8 were not significantly different ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}), likely due to a balance between cytokines produced by tumours and those produced by the human cells of reconstituted mice. In conclusion, HIS mice showed an inhibited tumour growth, but vaccination did not give a significant contribution over reconstitution to control the s.c. tumour.

Almost all rCD34 remained alive up to 40 days after tumour challenge, and were then killed to analyse metastatic dissemination of human SK-OV-3 tumour cells and parameters of the immune response. SK-OV-3 cells gave rise to lung metastases in 83--100% non-vaccinated mice (either untreated BRG and rCD34), whereas a significant inhibition of lung metastases was found in vaccinated rCD34 mice ([Table 1](#tbl1){ref-type="table"}).

To analyse the immune response elicited in HER-2-positive tumour-bearing vaccinated and non-vaccinated HIS mice, at the time of their killing (23 weeks of age) we studied human populations in peripheral blood, in the tumour and in lymphoid organs, total and specific antibody production, and cytokine production by human cells.

Vaccination-challenge procedure did neither modify the CD45+ level nor the frequency of human CD3+ and CD19+ populations in lymphoid organs of rCD34 mice nor the corresponding absolute cell yield, with the exception of a higher cell yield in thymus of vaccinated mice ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The NK cells, almost undetectable before challenge, increased during challenge of both vaccinated and non-vaccinated HIS mice up to about 2% of total peripheral blood cells ([Figure 2B](#fig2){ref-type="fig"}), and reached 7--8% in mesentheric lymph node (data not shown). Human plasma cells (cells positive for both human CD38 and CD138) were found in the spleen of challenged mice at heterogeneous levels: individual total IgG serum level was correlated to splenic plasma cell frequency ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}).

All tumours showed a rich human T lymphocyte infiltrate ([Figure 5](#fig5){ref-type="fig"}), often with a perivascular arrangement similar to what is seen in allograft rejection, mainly composed by cytotoxic T cells and, at a lower frequency, by helper and regulatory T cells. Numerous NK cells were also consistently present. Human CD11c-positive dendritic cells were found at heterogeneous levels. A semi-quantitative evaluation of tumour-infiltrating human populations showed an increased level of dendritic cells in rCD34 vaccinated over non-vaccinated mice, and such difference approached statistical significance ([Table 2](#tbl2){ref-type="table"}). CD45R+ B cells were not found in tumours (data not shown). A very rich murine leukocyte infiltrate with phagocytic features composed of neutrophils, macrophages and dendritic cells was also present in all the tumours ([Figure 5](#fig5){ref-type="fig"}).

After challenge, total human IgG levels in vaccinated rCD34 mice reached significantly higher and less dispersed levels than in non-vaccinated rCD34 mice ([Figure 3A](#fig3){ref-type="fig"}). Challenge elicited high levels of specific anti-HER-2 IgG antibodies in vaccinated rCD34 mice ([Figure 3B](#fig3){ref-type="fig"}, lanes 8--10), but provided the antigenic stimuli to induce trace amounts of anti-HER-2 IgG antibodies also in non-vaccinated mice ([Figure 3B](#fig3){ref-type="fig"}, lanes 5--7). Sera containing anti-HER-2 antibodies showed growth-inhibiting and ADCC activities against HER-2-positive human cancer cells ([Figure 3C](#fig3){ref-type="fig"}). Comparing the data obtained pre- and post challenge, challenge boosted the production of anti-HER-2 human IgG antibodies elicited by vaccination, but could even induce it at a lower level in non-vaccinated HIS mice.

Release of human cytokines by the spleen cells, cultured alone or in the presence of proliferation-blocked vaccine cells, was studied as a parameter of cell-mediated immune response. Human IFN-*γ* was spontaneously released at variable levels by the spleen cells of challenged rCD34 mice ([Figure 6](#fig6){ref-type="fig"}), whereas it had not been detected in rCD34 mice killed just after the completion of the vaccination (data not shown). The *in vitro* restimulation with vaccine cells induced only a slight, not significant increase of IFN-*γ* release ([Figure 6](#fig6){ref-type="fig"}, vaccine-restimulated groups). Significant levels of the secondary IFN-*γ*-inducible cytokine IP-10 were also detected, whereas only trace amounts of TNF-*α* were found at similar levels in vaccinated and non-vaccinated rCD34 mice ([Figure 6](#fig6){ref-type="fig"}).

Discussion
==========

In this paper, we studied HIS mice engrafted with two different human HSC: CD34^+^ and CD133^+^ cells. We then studied the ability of HIS mice to elicit a human immune reaction towards human HER-2-positive cancer cells.

Although the ability of CD34^+^ human cord blood HSC to reconstitute a human immune system in BRG mice has been extensively described ([@bib3]), freshly isolated CD133^+^ cord blood progenitors were not studied. In humans, CD133^+^ HSC have been already used to restore bone marrow function in allogeneic recipients ([@bib2]). However, its lymphopoietic potential has never been directly compared with that of CD34+ HSC in a same experimental HIS model. In this study, the two types of cord blood human HSC-engrafted BALB/c *Rag2*^−/−^; *Il2rg*^−/−^ mice showed similar levels and differentiation ability, giving about 50% human-circulating leukocytes at 5 weeks, long-term persistence of human cells in lymphoid organs and production of human antibodies. Noteworthy, in some regards, rCD133 mice showed a more robust human reconstitution although at early time points. Therefore, CD133+ cells show a partially different *in vivo* differentiation potential as compared with CD34^+^ cells and may provide a valuable alternative to CD34^+^ cell population for xenotransplantation.

The HIS rCD34 and rCD133 mice were randomised to a non-vaccinated group and a group vaccinated with an adjuvanted cell vaccine, consisting of human HER-2-positive cancer cells combined with systemic IL-12 administration. At the end of two monthly vaccination cycles mice were able to produce specific anti-HER-2 IgG human antibodies, whereas did not show changes in any other parameter studied (such as percentage and differentiation of circulating human populations and total human antibodies).

Potency of vaccine is known to determine the intensity of the immune response, with adjuvants having important roles. Allogeneicity and recombinant IL-12 were previously needed as adjuvants in HER-2 cell vaccines to break tolerance to HER-2 in transgenic HER-2 mice, eliciting a specific anti-HER-2 humoral response ([@bib22]). In the present study, combination of IL-12 with a cell vaccine carrying the adjuvant allogeneicity, since matching between engrafting human HSC and HER-2-positive cancer cell vaccine is highly unlikely, was able to elicit a specific humoral response. This suggest that the unsatisfactory immune responses so far obtained in most HIS models, also due to an incomplete immune matching of murine and human cells and cytokines ([@bib18]), can be at least partly overcome by the use of more powerful vaccines. The highest immune responses so far obtained with HIS mice were elicited by viral infections or viral vaccines ([@bib8]; [@bib13]; [@bib29]; [@bib14]; [@bib1]).

Then mice were challenged through the s.c. injection of the same live HER-2-positive cancer cells previously used as vaccine, to further evaluate the ability to obtain an immune response strong enough to lead to tumour rejection. Concerning the timing of vaccination, we chose to start the vaccinations as early as possible to vaccinate mice with the maximal engrafting levels and with the aim to perform two cycles of vaccination (corresponding to two months). Challenge was performed just after vaccination completion, when engraftment levels were still good. Tumour growth was actually delayed but inhibition was independent of vaccination and did not achieve tumour rejection. This could be due to escape mechanisms by tumour cells ([@bib4]) as well as to an incomplete response by HIS mice. These data are in agreement with the finding that MHC-mismatched tumour cells can coexist with human HSC without rejection ([@bib34]). However, the response elicited in vaccinated mice was able to almost completely abolish metastases.

Concerning antitumour immune activities of HIS mice, NK and cytotoxic T responses and production of IFN-*γ* have been reported for a few non-viral tumour models ([@bib15]; [@bib34]), generally leading to an inhibition of tumour growth. However, very few data on immune responses elicited by antitumour vaccines have been reported ([@bib10]). Here, we have shown that in HIS mice an adjuvanted tumour cell vaccine can elicit specific antibody responses, along with an increased dendritic tumour cell infiltrate. These components, combined to the presence of NK cells and IFN-*γ*, could have a role in inhibiting metastasis in HIS mice. We cannot rule out that a human anti-MHC response (elicited by the mismatching between immune engrafted cells and vaccine) could also contribute to the inhibition of lung metastases. The immune response elicited was not able to neutralise a bulk injection of tumour cells, but was able to effectively control the day-by-day seeding of lung metastatic cells. Such data confirm a huge amount of experimental studies in murine systems showing that even partial immune responses can efficiently fight metastatic dissemination but hardly control growing tumours ([@bib24]). Migration and motility, which are known to have a major role in metastatic process, were inhibited by trastuzumab ([@bib30]; [@bib36]). Similar effects could contribute to the dissociation of effects against tumour growth and metastases observed in our system.

This model could be exploited to obtain human monoclonal antibodies ([@bib10]; [@bib1]) against tumour targets. In particular, our adjuvanted vaccine could lead to the development of new fully human anti-HER-2 monoclonal antibodies to integrate the therapeutic activity of those already entered into the clinic ([@bib26]). A second interesting approach could be the study of the immunogenicity of different HER-2-positive cancer cell lines, in relation with different MHC haplotypes or with their natural as well as engineered cytokine production. SK-OV-3 cells produce several human cytokines, such as VEGF, IL-6, IL-8 and IL-15 ([@bib21]; [@bib11]; [@bib33] and our unpublished data) that could interact with the human effectors engrafting HIS mice. The incomplete function of immune system in HIS mice has also been attributed to a lack of human--mouse cross-reactivity of several cytokines, as an example murine IL-6 is not active on human cells ([@bib19]). IL-6 has pleiotropic activity ranging from immune suppression to induction of B-cell maturation ([@bib6]). The production of some human cytokines by proliferation-blocked (but live) SK-OV-3 vaccine cells, as well as by live SK-OV-3 challenge cells, could have had a role in the induction of the adaptive humoral response or in the immune responses observed in challenged HIS mice.

In conclusion, HIS mice were used to study the possibility of triggering *in vivo* a specific immune response against tumour antigens by human lymphocytes. Even though the immune response is still not complete, future refinements of this model could lead to a more realistic assessment of both the ability of a vaccine to induce immune responses in human lymphocytes and the efficacy (and limits) of the immune reactions elicited.
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![Kinetics of human populations in peripheral blood and of IgM and IgG human antibody levels in mice engrafted with human CD34+ or CD133+ HSC (indicated as rCD34 or rCD133, respectively). Mean and s.e. is shown (7--28 mice per group). \**P*\<0.05 at least at Wilcoxon non-parametric rank sum test between rCD34 and rCD133.](bjc2012394f1){#fig1}

![Vaccination and challenge with HER-2-positive human cancer cells in HIS mice. (**A**) Schedule of treatments. (**B**) Circulating human populations in HIS mice subjected to the vaccination-challenge experiment, tested at the following times: 5 week, assessment of human engrafting level and distribution of HIS mice in two matched groups; 15 weeks, after the completion of two vaccination cycles; 21--23 weeks, after tumour growth (sacrifice time). Open symbols: non-vaccinated; closed red symbols: vaccinated. Values of individual mice are shown. Continuous horizontal lines indicate median values.](bjc2012394f2){#fig2}

![Total and HER-2-specific human antibodies in rCD34 mice. (**A**). Total IgG (left) and total IgM (right) serum levels. Open symbols: non-vaccinated; closed red symbols: vaccinated. Values of individual mice are shown. Continuous horizontal lines indicate median values. (**B**) Anti-HER-2 antibodies detected through immunoprecipitation. Sera (a volume containing 1.5 *μ*g total human IgG) used to immunoprecipitate were: 1=anti-HER-2 MAb-positive control; 2=non-HIS, non-vaccinated BRG with growing tumour challenge; 3=non-vaccinated rCD34; 4=vaccinated rCD34; 5--7=non-vaccinated, challenged rCD34; 8--10=vaccinated and challenged rCD34. (**C**). *In vitro* effects of sera containing anti-HER-2 antibodies against HER-2-positive human cancer cells: growth inhibition (left panel) and antibody-dependent cellular cytotoxicity (ADCC, right panel). Mean and s.e.m. of five non-vaccinated (no vax) and six vaccinated (vax) rCD34 mice are shown (*P*\<0.05 at Student\'s *t*-test).](bjc2012394f3){#fig3}

![Inhibition of tumour growth of human HER-2-positive cancer cells in rCD34 mice *vs* control BRG mice (untreated or subjected to neonatal irradiation only). Mean tumour volumes and s.e. are shown (*n*=5--7 for treated mice, *n*=23 for untreated mice). Tumour volumes observed in rCD34 mice (vaccinated or not) were statistically smaller than those of control groups (untreated or irradiated) starting from day 19 (*P*\<0.05 at least at Student\'s *t*-test).](bjc2012394f4){#fig4}

![Human and murine tumour-infiltrating inflammatory cells. First two lines: immunohistochemistry with markers of human inflammatory cells: common marker of human T cells (hCD3+ in brown), helper T cells (CD4+ in brown), cytotoxic T cells (hCD8+ in brown), dendritic cells (hCD11c+ in brown), regulatory T cells (hFoxp3+ in red) and NK cells (hCD56+ in brown). Third line: immunohistochemistry with markers of murine inflammatory cells: neutrophils (mGR1+ in red), macrophages (mCD11b+ in red) and dendritic cells (mCD11c+ in red).](bjc2012394f5){#fig5}

![Human splenic engrafting and production of human cytokines by cells recovered from the spleen of HIS vaccinated or non-vaccinated mice after the challenge with live tumour cells. Total spleen cell yields ( × 10^6^) were: non-vaccinated, 6.2±1.3; vaccinated, 9.2±1.8 (not significant at Student\'s *t*-test or non-parametric test). (**A**) Cytofluorometric evaluation of human differentiated populations. Open symbols: non-vaccinated; closed red symbols: vaccinated. Values of individual mice are shown. Continuous horizontal lines indicate median values. (**B**) Cytokine production by the spleen cells cultured *in vitro* for 6 days alone (spontaneous) or in the presence of proliferation-blocked vaccine cells (restimulated). Symbols as in **A**.](bjc2012394f6){#fig6}

###### Inhibition of lung metastases of human HER-2-positive cancer cells in vaccinated rCD34 mice

                      **Lung metastases**                                                   
  ------------- ----- -------------------------------- ----- ------------------------------ --------
  Untreated      No   10/12                            83    15                             0--218
  Irradiation    No   5/6                              83    12                             0--61
  rCD34          No   6/6                              100   11                             2--50
  rCD34          Yes  3/7[a](#t1-fn1){ref-type="fn"}   43    0[b](#t1-fn2){ref-type="fn"}   0--20

*P*=0.049 at *χ*^2^ Fisher exact test *vs* non-vaccinated rCD34.

*P*=0.028 at non-parametric Wilcoxon rank sum test *vs* untreated.

###### Infiltrating human leucocytes in human tumours grown in rCD34 mice vaccinated or not

           **rCD34 individual mice**                                                                     
  -------- --------------------------- ----- ---- ----- ------ ----- -------- ----- -------- ----- ----- ----------
  hCD11c   \+                          \+    −    \+    \+     −     +++      \+    −        ++    ++     *P*=0.06
  hCD8     +++                         +++   −    ++    +++    +++   ++/+++   ++    ++/+++   +++   ++        NS
  hCD3     ++                          +++   −    +++   +++    +++   +++      +++   +++      +++   ++        NS
  hCD11b   −                           −     −    −     −      −     −        −     −        −     −         NS
  hCD56    NP                          ++    NP   \+    +/++   NP    ++       ++    NP       NP    \+        NS
                                                                                                              
  hCD4     NP                          ++    NP   +++   ++     NP    ++       ++    NP       NP    ++        NS
  Foxp3    NP                          NP    NP   ++    +++    NP    NP       +++   NP       NP    +++       NS

Abbreviations: NP=not performed; NS=not significant.

Low (−/+) *vs* high (++/+++) frequency of human cells.
